{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:24:12Z","timestamp":1788834252762,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCT Proof-of-Concept Trial Research Grant"},{"name":"NCT Proof-of-Concept Trial Research Grant"},{"name":"NCT Translational Research Grant in Precision Oncology"},{"name":"NCT Translational Research Grant in Precision Oncology"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1913A"],"award-info":[{"award-number":["01ZX1913A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1913B"],"award-info":[{"award-number":["01ZX1913B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma is the most serious type of skin cancer that frequently spreads to other organs of the human body. Especially melanoma metastases to the brain (intracranial metastases) are hard to treat and a major cause of death of melanoma patients. Little is known about molecular alterations and altered mechanisms that distinguish intra- from extracranial melanoma metastases. So far, almost all existing studies compared intracranial metastases from one set of patients to extracranial metastases of an another set of melanoma patients. This neglects the important facts that each melanoma is highly individual and that intra- and extracranial melanoma metastases from the same patient are more similar to each other than to melanoma metastases from other patients in the same organ. To overcome this, we compared the gene expression profiles of 16 intracranial metastases to their corresponding 21 patient-matched extracranial metastases in a personalized way using a three-state Hidden Markov Model (HMM) to identify altered genes for each individual metastasis pair. This enabled three major findings by considering the predicted gene expression alterations across all patients: (i) most frequently altered pathways include cytokine-receptor interaction, calcium signaling, ECM-receptor interaction, cAMP signaling, Jak-STAT and PI3K\/Akt signaling, (ii) immune-relevant signaling pathway genes were downregulated in intracranial metastases, and (iii) intracranial metastases were associated with a brain-like phenotype gene expression program. Further, the integration of all differentially expressed genes across the patient-matched melanoma metastasis pairs led to a set of 103 genes that were consistently down- or up-regulated in at least 11 of the 16 of the patients. This set of genes contained many genes involved in the regulation of immune responses, cell growth, cellular signaling and transport processes. An analysis of these genes in the TCGA melanoma cohort showed that the expression behavior of 11 genes was significantly associated with survival. Moreover, a comparison of the 103 genes to three closely related melanoma metastasis studies revealed a core set of eight genes that were consistently down- or upregulated in intra- compared to extracranial metastases in at least two of the three related studies (down: <jats:italic>CILP<\/jats:italic>, <jats:italic>DPT<\/jats:italic>, <jats:italic>FGF7<\/jats:italic>, <jats:italic>LAMP3<\/jats:italic>, <jats:italic>MEOX2<\/jats:italic>, <jats:italic>TMEM119<\/jats:italic>; up: <jats:italic>GLDN<\/jats:italic>, <jats:italic>PMP2<\/jats:italic>) including <jats:italic>FGF7<\/jats:italic> that was also significantly associated with survival. Our findings contribute to a better characterization of genes and pathways that distinguish intra- from extracranial melanoma metastasis and provide important hints for future experimental studies to identify potential targets for new therapeutic approaches.<\/jats:p>","DOI":"10.1186\/s40478-024-01764-5","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T14:02:55Z","timestamp":1714140175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs"],"prefix":"10.1186","volume":"12","author":[{"given":"Theresa","family":"Kraft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Gr\u00fctzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-053X","authenticated-orcid":false,"given":"Michael","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"1764_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"M Davies","year":"2011","unstructured":"Davies M, Liu P, McIntyre S, Kim K, Papadopoulos N, Hwu W et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687\u201396. https:\/\/doi.org\/10.1002\/cncr.25634","journal-title":"Cancer"},{"key":"1764_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","volume":"24","author":"C Alvarez-Breckenridge","year":"2019","unstructured":"Alvarez-Breckenridge C, Giobbie A, Hurder Gill C, Bertalan M, Stocking K, Kaplan A, Nayyar N et al (2019) Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control. Oncologist 24:671\u2013679. https:\/\/doi.org\/10.1634\/theoncologist.2018-0306","journal-title":"Oncologist"},{"key":"1764_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2326-6066.CIR-20-0905","volume":"9","author":"M Phadke","year":"2021","unstructured":"Phadke M, Chen Z, Li J, Mohamed E, Davies M, Smalley I et al (2021) Targeted therapy given after Anti-PD-1 leads to prolonged responses in mouse melanoma models through sustained antitumor immunity. Cancer Immunol Res 9:554\u2013567. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0905","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1764_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A et al (2017) Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"1764_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"key":"1764_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"2","author":"A Menzies","year":"2021","unstructured":"Menzies A, Amaria R, Rozeman E, Huang A, Tetzlaff M, Wiel B et al (2021) Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2:301\u2013309. https:\/\/doi.org\/10.1038\/s41591-020-01188-3","journal-title":"Nat Med"},{"issue":"11","key":"1764_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/neuonc\/noab094","volume":"23","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O et al (2021) Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol 23(11):1961\u20131973. https:\/\/doi.org\/10.1093\/neuonc\/noab094","journal-title":"Neuro Oncol"},{"issue":"12","key":"1764_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD et al (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692\u20131704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3","journal-title":"Lancet Oncol"},{"issue":"16","key":"1764_CR9","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/cancers15164088","volume":"15","author":"A Nowacka","year":"2023","unstructured":"Nowacka A, Fajkiel-Madajczyk A, Ohla J, Wozniak-Dabrowska K, Liss S, Gryczka K et al (2023) Current treatment of melanoma brain metastases. Cancers (Basel) 15(16):4088. https:\/\/doi.org\/10.3390\/cancers15164088","journal-title":"Cancers (Basel)"},{"key":"1764_CR10","doi-asserted-by":"publisher","first-page":"113287","DOI":"10.1016\/j.ejca.2023.113287","volume":"192","author":"AE Dohm","year":"2023","unstructured":"Dohm AE, Nakashima JY, Kalagotla H, Jiang SX, Tang JD, Bhandari M et al (2023) Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer 192:113287. https:\/\/doi.org\/10.1016\/j.ejca.2023.113287","journal-title":"Eur J Cancer"},{"key":"1764_CR11","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","volume":"39","author":"GV Long","year":"2021","unstructured":"Long GV, Atkinson V, Lo S, Guminski AD, Sandhu SK, Brown MP, Gonzalez M et al (2021) Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J Clin Oncol 39:9508. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9508","journal-title":"J Clin Oncol"},{"key":"1764_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","volume":"174","author":"A Gonzalez-Martin","year":"2022","unstructured":"Gonzalez-Martin A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H et al (2022) PAOLA1\/ENGOT-ov25 investigators. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer\u202f: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial. Eur J Cancer 174:221\u2013231. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.022","journal-title":"Eur J Cancer"},{"key":"1764_CR13","doi-asserted-by":"publisher","first-page":"113542","DOI":"10.1016\/j.ejca.2024.113542","volume":"199","author":"M Mandala","year":"2024","unstructured":"Mandala M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D et al (2024) Combined immunotherapy in melanoma patients with brain metastases: a multicenter international studyl. Eur J Cancer 199:113542. https:\/\/doi.org\/10.1016\/j.ejca.2024.113542","journal-title":"Eur J Cancer"},{"key":"1764_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/PPO.0000000000000237","volume":"23","author":"I Oliva","year":"2017","unstructured":"Oliva I, Tawbi H, Davies M (2017) Melanoma brain metastases: current areas of investigation and future directions. Cancer J 23:68\u201374. https:\/\/doi.org\/10.1097\/PPO.0000000000000237","journal-title":"Cancer J"},{"key":"1764_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/exd.14286","volume":"31","author":"M Phadke","year":"2022","unstructured":"Phadke M, Ozgun A, Eroglu Z, Smalley K (2022) Melanoma brain metastases: biological basis and novel therapeutic strategies. Exp Dermatol 31:31\u201342. https:\/\/doi.org\/10.1111\/exd.14286","journal-title":"Exp Dermatol"},{"key":"1764_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"N Hayward","year":"2017","unstructured":"Hayward N, Wilmott J, Waddell N, Johansson P, Field M, Nones K et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545:175\u2013180. https:\/\/doi.org\/10.1038\/nature22071","journal-title":"Nature"},{"issue":"1","key":"1764_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cam4.50","volume":"2","author":"H Niessner","year":"2013","unstructured":"Niessner H, Forschner A, Klumpp B, Honegger J, Witte M, Aa Bornemann (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2(1):76\u201385. https:\/\/doi.org\/10.1002\/cam4.50","journal-title":"Cancer Med."},{"key":"1764_CR18","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen G, Chakravarti N, Aardalen K, Lazar A, Tetzlaff M, Wubbenhorst B et al (2014) Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20:5537\u20135546. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3003","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1764_CR19","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-16-0064","volume":"22","author":"H Niessner","year":"2016","unstructured":"Niessner H, Schmitz J, Tabatabai G, Schmid A, Calaminus C, Sinnberg T et al (2016) PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res 22(23):5818\u20135828. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0064","journal-title":"Clin Cancer Res"},{"key":"1764_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"O Brastianos","year":"2015","unstructured":"Brastianos O, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164\u20131177. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369","journal-title":"Cancer Discov"},{"key":"1764_CR21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jid.2023.01.011","volume":"143","author":"D Westphal","year":"2023","unstructured":"Westphal D, Meinhardt M, Gr\u00fctzmann K, Sch\u00f6ne L, Steininger J, Neuhaus L et al (2023) Identification of epigenetically regulated genes distinguishing intracranial from extracranial melanoma metastases. J Investig Dermatol 143:1233\u20131245. https:\/\/doi.org\/10.1016\/j.jid.2023.01.011","journal-title":"J Investig Dermatol"},{"issue":"14","key":"1764_CR22","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","volume":"185","author":"J Biermann","year":"2022","unstructured":"Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A et al (2022) Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell 185(14):2591\u20132608. https:\/\/doi.org\/10.1016\/j.cell.2022.06.007","journal-title":"Cell"},{"key":"1764_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","volume":"185","author":"H Gonzalez","year":"2022","unstructured":"Gonzalez H, Mei W, Robles I, Hagerling C, Allen B, Okholm T et al (2022) Cellular architecture of human brain metastases. Cell 185:729\u2013745. https:\/\/doi.org\/10.1016\/j.cell.2021.12.043","journal-title":"Cell"},{"key":"1764_CR24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/neuonc\/nou107","volume":"16","author":"D Marzese","year":"2014","unstructured":"Marzese D, Scolyer R, Roqu\u00e9 M, Vargas-Roig L, Huynh J, Wilmott J et al (2014) DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro Oncol 16:1499\u20131509. https:\/\/doi.org\/10.1093\/neuonc\/nou107","journal-title":"Neuro Oncol"},{"issue":"1","key":"1764_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41598-022-24940-w","volume":"13","author":"T Kraft","year":"2023","unstructured":"Kraft T, Gr\u00fctzmann K, Meinhardt M, Meier F, Westphal D, Seifert M (2023) Patient-specific identification of genome-wide DNA-methylation differences between intracranial and extracranial melanoma metastases. Sci Rep 13(1):444. https:\/\/doi.org\/10.1038\/s41598-022-24940-w","journal-title":"Sci Rep"},{"key":"1764_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290","volume":"9","author":"G Fischer","year":"2019","unstructured":"Fischer G, Jalali A, Kircher D, Lee W, McQuade J, Haydu L et al (2019) Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov 9:628\u2013645. https:\/\/doi.org\/10.1158\/2159-8290","journal-title":"Cancer Discov"},{"key":"1764_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.csbj.2024.02.013","volume":"23","author":"K Gr\u00fctzmann","year":"2024","unstructured":"Gr\u00fctzmann K, Kraft T, Meinhardt M, Meier F, Westphal D, Seifert M (2024) Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups. Comput Struct Biotechnol J 23:1036\u20131050. https:\/\/doi.org\/10.1016\/j.csbj.2024.02.013","journal-title":"Comput Struct Biotechnol J"},{"key":"1764_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers13040731","volume":"13","author":"R Varaljai","year":"2021","unstructured":"Varaljai R, Horn S, Sucker A, Piercianek D, Schmitt V, Carpinteiro A et al (2021) Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanoma. Cancers (Basel) 13:731. https:\/\/doi.org\/10.3390\/cancers13040731","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1764_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):47\u201347. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1764_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","volume":"22","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22(12):1540\u20131542. https:\/\/doi.org\/10.1093\/bioinformatics\/btl117","journal-title":"Bioinformatics"},{"key":"1764_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","volume":"31","author":"F Murtagh","year":"2014","unstructured":"Murtagh F, Legendre P (2014) Ward\u2019s hierarchical agglomerative clustering method: Which algorithms implement ward\u2019s criterion? J Classif 31:274\u2013295. https:\/\/doi.org\/10.1007\/s00357-014-9161-z","journal-title":"J Classif"},{"key":"1764_CR32","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/bioinformatics\/btr199","volume":"27","author":"M Seifert","year":"2011","unstructured":"Seifert M, Strickert M, Schliep A, Grosse I (2011) Exploiting prior knowledge and gene distances in the analysis of tumor expression profiles with extended Hidden Markov Models. Bioinformatics 27:1645\u201352. https:\/\/doi.org\/10.1093\/bioinformatics\/btr199","journal-title":"Bioinformatics"},{"key":"1764_CR33","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1371\/journal.pone.0100295","volume":"9","author":"M Seifert","year":"2014","unstructured":"Seifert M, Abou-El-Ardat K, Friedrich B, Klink B, Deutsch A (2014) Autoregressive high-order hidden markov models: expoiting local chromosomal dependencies in the analysis of tumor expression profiles. PloS One 9:100295. https:\/\/doi.org\/10.1371\/journal.pone.0100295","journal-title":"PloS One"},{"issue":"11","key":"1764_CR34","doi-asserted-by":"publisher","first-page":"1007460","DOI":"10.1371\/journal.pcbi.1007460","volume":"15","author":"M Seifert","year":"2019","unstructured":"Seifert M, Peitzsch C, Gorodetska I, B\u00f6rner C, Klink B, Dubrovska A (2019) Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse. PLoS Comput Biol 15(11):1007460. https:\/\/doi.org\/10.1371\/journal.pcbi.1007460","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"1764_CR35","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/cancers12061696","volume":"12","author":"M Seifert","year":"2020","unstructured":"Seifert M, Schackert G, Temme A, Schr\u00f6ck E, Deutsch A, Klink B (2020) Molecular characterization of astrocytoma progression towards secondary glioblastomas utilizing patient-matched tumor pairs. Cancers 12(6):1696. https:\/\/doi.org\/10.3390\/cancers12061696","journal-title":"Cancers"},{"key":"1764_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M (2023) KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res 51:587\u2013592. https:\/\/doi.org\/10.1093\/nar\/gkac963","journal-title":"Nucleic Acids Res"},{"key":"1764_CR37","doi-asserted-by":"publisher","unstructured":"Tenenbaum D, Maintainer BP (2023) KEGGREST: Client-side REST Access to the Kyoto Encyclopedia of Genes and Genomes (KEGG). https:\/\/doi.org\/10.18129\/B9.bioc.KEGGREST. R package version 1.40.1","DOI":"10.18129\/B9.bioc.KEGGREST"},{"key":"1764_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2307\/2346101","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289\u2013300. https:\/\/doi.org\/10.2307\/2346101","journal-title":"J R Stat Soc Ser B"},{"key":"1764_CR39","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z et al (2021) ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb) 2:100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141","journal-title":"Innovation (Camb)"},{"issue":"1","key":"1764_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"U Consortium","year":"2023","unstructured":"Consortium U (2023) UniProt: the Universal Protein knowledgebase in 2023. Nucleic Acids Res 51(1):523\u2013531. https:\/\/doi.org\/10.1093\/nar\/gkac1052","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1764_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpbi.5","volume":"54","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S et al (2016) The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinf 54(1):1\u201330. https:\/\/doi.org\/10.1002\/cpbi.5","journal-title":"Curr Protoc Bioinf"},{"key":"1764_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Research Network","year":"2015","unstructured":"The Cancer Genome Atlas Research Network (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u201396. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","journal-title":"Cell"},{"key":"1764_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","volume":"20","author":"A Boire","year":"2020","unstructured":"Boire A, Brastianos P, Garzia L, Valiente M (2020) Brain metastasis. Nat Rev Cancer 20:4\u201311. https:\/\/doi.org\/10.1038\/s41568-019-0220-y","journal-title":"Nat Rev Cancer"},{"key":"1764_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/neup.12235","volume":"36","author":"J Satoh","year":"2016","unstructured":"Satoh J, Kino Y, Asahina N, Takitani M, Junko M, Ishida T, Saito Y (2016) TMEM119 marks a subset of microglia in the human brain. Neuropathology 36:39\u201349. https:\/\/doi.org\/10.1111\/neup.12235","journal-title":"Neuropathology"},{"issue":"5","key":"1764_CR45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4149\/neo_2018_171218N824","volume":"65","author":"L Tian","year":"2018","unstructured":"Tian L, Tao Z, Ye H, Li G, Zhan Z, Tuo H (2018) Over-expression of MEOX2 promotes apoptosis through inhibiting the PI3K\/Akt pathway in laryngeal cancer cells. Neoplasma 65(5):745\u2013752. https:\/\/doi.org\/10.4149\/neo_2018_171218N824","journal-title":"Neoplasma"},{"issue":"1","key":"1764_CR46","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcb.27438","volume":"120","author":"A Shang","year":"2019","unstructured":"Shang A, Zhou C, Bian G, Chen W, Lu W, Wang W, Li D (2019) miR-381-3p restrains cervical cancer progression by downregulating FGF7. J Cell Biochem 120(1):778\u2013789. https:\/\/doi.org\/10.1002\/jcb.27438","journal-title":"J Cell Biochem"},{"issue":"12","key":"1764_CR47","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/ijc.26328","volume":"130","author":"M Yamatoji","year":"2012","unstructured":"Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, Ogawara K et al (2012) Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer 130(12):2903\u20132911. https:\/\/doi.org\/10.1002\/ijc.26328","journal-title":"Int J Cancer"},{"key":"1764_CR48","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3389\/fgene.2022.862264","volume":"13","author":"X Sun","year":"2022","unstructured":"Sun X, Yang N, Zhou X, Dai H, Li Q, Feng A et al (2022) CILP, a putative gene associated with immune infiltration in breast cancer brain metastases. Front Genet 13:1165. https:\/\/doi.org\/10.3389\/fgene.2022.862264","journal-title":"Front Genet"},{"key":"1764_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-021-02781-x","volume":"19","author":"T Sun","year":"2021","unstructured":"Sun T, Bi F, Liu Z, Yang Q (2021) TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB\/PI3K\/AKT signaling pathway. J Trans Med 19:1\u201313. https:\/\/doi.org\/10.1186\/s12967-021-02781-x","journal-title":"J Trans Med"},{"issue":"1","key":"1764_CR50","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41467-022-29516-w","volume":"13","author":"C Hoffmann","year":"2022","unstructured":"Hoffmann C, Noel F, Grandclaudon M, Massenet-Regad L, Michea P, Sirven P et al (2022) PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity. Nat Commun 13(1):1983. https:\/\/doi.org\/10.1038\/s41467-022-29516-w","journal-title":"Nat Commun"},{"issue":"3","key":"1764_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/pcmr.12760","volume":"32","author":"SA Graf","year":"2019","unstructured":"Graf SA, Heppt MV, Wessely A, Krebs S, Kammerbauer C, Hornig E et al (2019) The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion. Pigment Cell Melanoma Res 32(3):424\u2013434. https:\/\/doi.org\/10.1111\/pcmr.12760","journal-title":"Pigment Cell Melanoma Res"},{"key":"1764_CR52","doi-asserted-by":"publisher","first-page":"1608132","DOI":"10.1080\/2162402X.2019.1608132","volume":"8","author":"H Chen","year":"2019","unstructured":"Chen H, Yang M, Wang Q, Song F, Li X, Chen K (2019) The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. Oncoimmunology 8:1608132. https:\/\/doi.org\/10.1080\/2162402X.2019.1608132","journal-title":"Oncoimmunology"},{"issue":"5","key":"1764_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12669","volume":"21","author":"H Huang","year":"2021","unstructured":"Huang H, Hao Z, Long L, Yin Z, Wu C, Zhou X, Zhang B (2021) Dermatopontin as a potential pathogenic factor in endometrial cancer. Oncol Lett 21(5):1\u20138. https:\/\/doi.org\/10.3892\/ol.2021.12669","journal-title":"Oncol Lett"},{"key":"1764_CR54","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/OTT.S164045","volume":"11","author":"P Zheng","year":"2018","unstructured":"Zheng P, Wang W, Ji M, Zhu Q, Feng Y, Zhou F, He Q (2018) TMEM119 promotes gastric cancer cell migration and invasion through STAT3 signaling pathway. OncoTargets Ther 11:5835\u20135844. https:\/\/doi.org\/10.2147\/OTT.S164045","journal-title":"OncoTargets Ther"},{"key":"1764_CR55","doi-asserted-by":"publisher","unstructured":"Barbai T, Fej\u0151s Z, Puskas L, T\u00edm\u00e1r J, R\u00e1s\u00f3 E (2015) The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma. Oncotarget 6:29111\u201329128 https:\/\/doi.org\/10.18632\/oncotarget.5059","DOI":"10.18632\/oncotarget.5059"},{"key":"1764_CR56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12935-021-02350-8","volume":"21","author":"P Yang","year":"2021","unstructured":"Yang P, Chen W, Xu H, Yang J, Jiang J, Jiang Y, Xu G (2021) Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway. Cancer Cell Int 21:635. https:\/\/doi.org\/10.1186\/s12935-021-02350-8","journal-title":"Cancer Cell Int"},{"key":"1764_CR57","doi-asserted-by":"publisher","first-page":"6630295","DOI":"10.1155\/2021\/6630295","volume":"2021","author":"S Dwivedi","year":"2021","unstructured":"Dwivedi S, Rend\u00f3n-Huerta E, Ortiz-Navarrete V, Monta\u00f1o L (2021) CD38 and regulation of the immune response cells in cancer. J Oncol 2021:6630295. https:\/\/doi.org\/10.1155\/2021\/6630295","journal-title":"J Oncol"},{"key":"1764_CR58","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms23020794","volume":"23","author":"R Xie","year":"2022","unstructured":"Xie R, Li B, Jia K, Li Y (2022) Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci 23:794. https:\/\/doi.org\/10.3390\/ijms23020794","journal-title":"Int J Mol Sci"},{"key":"1764_CR59","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40257-018-0346-9","volume":"19","author":"M Kuske","year":"2018","unstructured":"Kuske M, Rauschenberg R, Garzarolli M, Meredyth-Steward M, Beissert S, Troost E et al (2018) Melanoma brain metastases: local therapies, targeted therapies, immune checkpoint inhibitors and their combinations - chances and challenges. Am J Clin Dermatol 19:529\u2013541. https:\/\/doi.org\/10.1007\/s40257-018-0346-9","journal-title":"Am J Clin Dermatol"},{"key":"1764_CR60","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.30594","volume":"123","author":"D Westphal","year":"2017","unstructured":"Westphal D, Glitze Olivia I, Niessner H (2017) Molecular insights into melanoma brain metastases. Cancer 123:2163\u20132175. https:\/\/doi.org\/10.1002\/cncr.30594","journal-title":"Cancer"},{"key":"1764_CR61","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3390\/ijms23052644","volume":"23","author":"V Koroknai","year":"2022","unstructured":"Koroknai V, Sz\u00e1sz I, J\u00e1mbor K, Bal\u00e1zs M (2022) Cytokine and chemokine receptor patterns of human malignant melanoma cell lines. Int J Mol Sci 23:2644. https:\/\/doi.org\/10.3390\/ijms23052644","journal-title":"Int J Mol Sci"},{"key":"1764_CR62","doi-asserted-by":"publisher","first-page":"9483","DOI":"10.1158\/0008-5472.CAN-05-4227","volume":"66","author":"N Dumaz","year":"2006","unstructured":"Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin J et al (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66:9483\u20139491. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4227","journal-title":"Cancer Res"},{"issue":"6","key":"1764_CR63","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrc.2017.18","volume":"17","author":"G Monteith","year":"2017","unstructured":"Monteith G, Prevarskaya N, Roberts-Thomson S (2017) The calcium-cancer signalling nexus. Nat Rev Cancer 17(6):367\u2013380. https:\/\/doi.org\/10.1038\/nrc.2017.18","journal-title":"Nat Rev Cancer"},{"issue":"7942","key":"1764_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","volume":"613","author":"D Hausmann","year":"2023","unstructured":"Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK et al (2023) Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature 613(7942):179\u2013186. https:\/\/doi.org\/10.1038\/s41586-022-05520-4","journal-title":"Nature"},{"issue":"1","key":"1764_CR65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"C Arvanitis","year":"2020","unstructured":"Arvanitis C, Ferraro G, Jain R (2020) The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1764_CR66","doi-asserted-by":"publisher","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","volume":"8","author":"S Tiwary","year":"2018","unstructured":"Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH (2018) Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep 8(1):8267. https:\/\/doi.org\/10.1038\/s41598-018-26636-6","journal-title":"Sci Rep"},{"key":"1764_CR67","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag G, Schaefer J, Smolkin M, Deacon D, Shea S, Dengel L et al (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72:1070\u20131080. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3218","journal-title":"Cancer Res"},{"key":"1764_CR68","doi-asserted-by":"publisher","first-page":"573141","DOI":"10.3389\/fonc.2020.573141","volume":"18","author":"K Kang","year":"2020","unstructured":"Kang K, Xie F, Mao J, Bai Y, Wang X (2020) Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front Oncol 18:573141. https:\/\/doi.org\/10.3389\/fonc.2020.573141","journal-title":"Front Oncol"},{"key":"1764_CR69","doi-asserted-by":"publisher","first-page":"914730","DOI":"10.3389\/fphar.2022.914730","volume":"13","author":"Q Wu","year":"2022","unstructured":"Wu Q, Tu H, Li J (2022) Multifaceted roles of chemokine C-X-C motif ligand 7 in inflammatory diseases and cancer. Front Pharmacol 13:914730. https:\/\/doi.org\/10.3389\/fphar.2022.914730","journal-title":"Front Pharmacol"},{"key":"1764_CR70","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41419-021-04231-4","volume":"12","author":"Y-H Wang","year":"2021","unstructured":"Wang Y-H, Shen C-Y, Lin S-C, Kuo W-H, Hsu Y-L, Wang W-C et al (2021) Monocytes secrete CXCL7 to promote breast cancer progression. Cell Death Disease 12:1090. https:\/\/doi.org\/10.1038\/s41419-021-04231-4","journal-title":"Cell Death Disease"},{"issue":"1","key":"1764_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/noajnl\/vdaa140","volume":"2","author":"T Amaral","year":"2020","unstructured":"Amaral T, Niessner H, Sinnberg T, Thomas I, Meiwes A, Garbe C, Garzarolli M et al (2020) An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study. Neurooncol Adv 2(1):140. https:\/\/doi.org\/10.1093\/noajnl\/vdaa140","journal-title":"Neurooncol Adv"},{"issue":"2","key":"1764_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/neuonc\/noab159","volume":"24","author":"C Tehranian","year":"2022","unstructured":"Tehranian C, Fankhauser L, Harter PN, Ratcliffe CDH, Zeiner PS, Messmer JM, Hoffmann DC et al (2022) The PI3K\/Akt\/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro Oncol 24(2):213\u2013225. https:\/\/doi.org\/10.1093\/neuonc\/noab159","journal-title":"Neuro Oncol"},{"issue":"2","key":"1764_CR73","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.canlet.2015.09.004","volume":"369","author":"BR Achyut","year":"2015","unstructured":"Achyut BR, Shankar A, Iskander AS, Ara R, Angara K, Zeng P, Knight RA et al (2015) Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. Cancer Lett 369(2):416\u201326. https:\/\/doi.org\/10.1016\/j.canlet.2015.09.004","journal-title":"Cancer Lett"},{"key":"1764_CR74","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.neuron.2021.05.025","volume":"109","author":"TK Baldwin","year":"2021","unstructured":"Baldwin TK, Tan CX, Strader ST, Jiang C, Savage JT et al (2021) HepaCAM controls astrocyte self-organization and coupling. Neuron 109:2427\u2013244210. https:\/\/doi.org\/10.1016\/j.neuron.2021.05.025","journal-title":"Neuron"},{"key":"1764_CR75","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4161\/cam.3.4.9246","volume":"3","author":"MC Moh","year":"2009","unstructured":"Moh MC, Shen S (2009) The roles of cell adhesion molecules in tumor suppression and cell migration. Cell Adh Migr 3:334\u2013336. https:\/\/doi.org\/10.4161\/cam.3.4.9246","journal-title":"Cell Adh Migr"},{"issue":"9","key":"1764_CR76","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3390\/cancers14092151","volume":"14","author":"I B\u00f6hme-Sch\u00e4fer","year":"2022","unstructured":"B\u00f6hme-Sch\u00e4fer I, L\u00f6rentz S, Bosserhoff A (2022) Role of amino acid transporter SNAT1\/SLC38A1 in human melanoma. Cancers (Basel) 14(9):2151. https:\/\/doi.org\/10.3390\/cancers14092151","journal-title":"Cancers (Basel)"},{"key":"1764_CR77","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2018.36.4_suppl.419","volume":"36","author":"N Okano","year":"2018","unstructured":"Okano N, Kawai K, Yamauchi Y, Kobayashi T, Naruge D, Nagashima F, Endou H, Furuse J (2018) First-in-human phasestudy of JPH203 in patients with advanced solid tumors. J Clin Oncol 36:419. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.419","journal-title":"J Clin Oncol"},{"issue":"17","key":"1764_CR78","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.3390\/ijms21176156","volume":"21","author":"S Br\u00f6er","year":"2020","unstructured":"Br\u00f6er S (2020) Amino acid transporters as targets for cancer therapy: why, where, when, and how. Int J Mol Sci 21(17):6156. https:\/\/doi.org\/10.3390\/ijms21176156","journal-title":"Int J Mol Sci"},{"key":"1764_CR79","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.4161\/cc.25511","volume":"12","author":"K Yamada","year":"2013","unstructured":"Yamada K, Ono M, Bensaddek D, Lamond A, Rocha S (2013) FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21. Cell Cycle 12:2348\u201354. https:\/\/doi.org\/10.4161\/cc.25511","journal-title":"Cell Cycle"},{"key":"1764_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejbt.2023.12.002","volume":"68","author":"Y Cao","year":"2024","unstructured":"Cao Y, Cao D, Zhu T (2024) Circular RNA FMN2 motivates colorectal cancer development by mediating tumor-associated macrophage polarization by controlling the microRNA-150-5p\/PIK3R3 axis. Electron J Biotechnol 68:31\u201340. https:\/\/doi.org\/10.1016\/j.ejbt.2023.12.002","journal-title":"Electron J Biotechnol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01764-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T01:07:22Z","timestamp":1714180042000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01764-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01764-5","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the TU Dresden (EK 48022018). Written informed consent was obtained for the use of FFPE tumor material for transcriptome analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no Conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}